174 related articles for article (PubMed ID: 7493545)
1. Characterization of the metabolites of the peptidomimetic human immunodeficiency virus type 1 protease inhibitor SK&F 107461 in rats using liquid chromatography/mass spectrometry.
Potts W; van Horn R; Anderson K; Blake T; Garver E; Joseph G; Dreyer G; Shu A; Heys R; Fong KL
Drug Metab Dispos; 1995 Aug; 23(8):799-805. PubMed ID: 7493545
[TBL] [Abstract][Full Text] [Related]
2. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
[TBL] [Abstract][Full Text] [Related]
4. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the anticoagulant peptide, MDL 28,050, in rats.
Knadler MP; Ackermann BL; Coutant JE; Hurst GH
Drug Metab Dispos; 1992; 20(1):89-95. PubMed ID: 1347003
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of 5-chloro-3-phenylthioindole-2-carboxamide (L-734,005) in rhesus monkeys and rat liver microsomes to a potent HIV-1 reverse transcriptase inhibitor.
Balani SK; Goldman ME; Kauffman LR; Varga SL; O'Brien JA; Smith SJ; Olah TV; Ramjit HG; Schorn TW; Pitzenberger SM
Drug Metab Dispos; 1993; 21(4):598-604. PubMed ID: 7690697
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of a new HIV-1 reverse transcriptase inhibitor, 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one (L-696,229), in rat and liver slices.
Balani SK; Pitzenberger SM; Kauffman LR; Arison BH; Ramjit HG; Goldman ME; O'Brien JA; King JD; Hoffman JM; Rooney CS
Drug Metab Dispos; 1992; 20(6):869-76. PubMed ID: 1283569
[TBL] [Abstract][Full Text] [Related]
9. In vivo metabolism of the leukotriene receptor antagonist, 5-(2-dodecylphenyl)-4,6-dithianonanedioic acid (SK&F 102,081) in the guinea pig.
Newton JF; Straub KM; Kuo GY; Perchonock CD; McCarthy ME; Gleason JG; Lynn RK
Drug Metab Dispos; 1987; 15(2):168-76. PubMed ID: 2882973
[TBL] [Abstract][Full Text] [Related]
10. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
Balani SK; Xu X; Pratha V; Koss MA; Amin RD; Dufresne C; Miller RR; Arison BH; Doss GA; Chiba M; Freeman A; Holland SD; Schwartz JI; Lasseter KC; Gertz BJ; Isenberg JI; Rogers JD; Lin JH; Baillie TA
Drug Metab Dispos; 1997 Nov; 25(11):1282-7. PubMed ID: 9351905
[TBL] [Abstract][Full Text] [Related]
11. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
13. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.
Riska PS; Joseph DP; Dinallo RM; Davidson WC; Keirns JJ; Hattox SE
Drug Metab Dispos; 1999 Dec; 27(12):1434-47. PubMed ID: 10570025
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
Balani SK; Kauffman LR; Arison BH; Olah TV; Goldman ME; Varga SL; O'Brien JA; Ramjit HG; Rooney CS; Hoffman JM
Drug Metab Dispos; 1994; 22(2):200-5. PubMed ID: 7516852
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
Balani SK; Pitzenberger SM; Schwartz MS; Ramjit HG; Thompson WJ
Drug Metab Dispos; 1995 Feb; 23(2):185-9. PubMed ID: 7736909
[TBL] [Abstract][Full Text] [Related]
16. Toxicokinetics and biotransformation of 3-(4-methylbenzylidene)camphor in rats after oral administration.
Völkel W; Colnot T; Schauer UM; Broschard TH; Dekant W
Toxicol Appl Pharmacol; 2006 Oct; 216(2):331-8. PubMed ID: 16806338
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates.
Kitani M; Miyamoto G; Nagasawa M; Yamada T; Matsubara J; Uchida M; Odomi M
Drug Metab Dispos; 1997 Jun; 25(6):663-74. PubMed ID: 9193867
[TBL] [Abstract][Full Text] [Related]
18. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of alpha-phosphonosulfonate squalene synthase inhibitors. I. Disposition of a farnesylethyl alpha-phosphonosulfonate and ester prodrugs in rats.
Lan SJ; Hsieh DC; Hillyer JW; Fancher RM; Rinehart KJ; Warrack BM; White RE
Drug Metab Dispos; 1998 Oct; 26(10):993-1000. PubMed ID: 9763405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
